Company news
Tasly Pharmaceutical Group Co. Ltd. news in 2026
Tasly Pharmaceutical Group Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Report for Q3 2026
October 23, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Termination of an R&D Project and Provision for Asset Impairment
October 23, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions of the 26th Meeting of the 9th Board of Directors
October 23, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by Subsidiary
October 15, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining the Drug Clinical Trial Approval Notice
October 14, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Election of Employee Director
October 12, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by Subsidiary
October 9, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
October 8, 2026
Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors
September 24, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 11, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction
August 28, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 27, 2026
Announcement on Subsidiary Obtaining the Notice of Approval for Clinical Trial
August 21, 2026
Announcement on Amendments to the Articles of Association
August 10, 2026
Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for Injection
July 17, 2026
Announcement on Semi-annual Performance for 2026
July 14, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
June 25, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 15, 2026
Announcement on Remuneration Plan for Directors and Senior Management Members in 2026
June 8, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 21, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 18, 2026
Announcement on Change of Accounting Policies
April 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 17, 2026
Announcement on Guarantee Estimate for 2026
March 23, 2026
Announcement on Annual Key Operating Data Report for 2025
March 19, 2026
Announcement on Resignation of Senior Management Member
March 6, 2026
Preliminary Earnings Estimate for 2025
February 6, 2026
Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
January 24, 2026